Alamar Biosciences (ALMR)
Supplies NULISA assays and ARGO HT automation for protein-biomarker measurement.
$32.24
vs last close−0.98 (−2.95%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Revenue | 26 | 29 |
| Cost of revenue | 12 | 12 |
| Gross profit | 14 | 18 |
| 27 | 31 | |
| Research & development | 13 | 14 |
| Selling, general & administrative | 14 | 17 |
| Operating income | −12 | −14 |
| −9 | 0 | |
| Interest income | 1 | 2 |
| Interest expense | 0 | 0 |
| Other non-operating income | 8 | 0 |
| Income before tax | −21 | −13 |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | −21 | −13 |
| Net income | −21 | −13 |
| EPS, basic | −$0.31 | −$0.22 |
| EPS, diluted | −$0.31 | −$0.22 |
| Weighted average shares, basic | 69 | 59 |
| Weighted average shares, diluted | 69 | 59 |
| EBITDA | −19 | −13 |
| Depreciation & amortization | 1 | 0 |
| EBIT | −21 | −13 |